An early feasibility study of the Nativis Voyager ® device in patients with recurrent glioblastoma: first cohort in US

• Published in: CNS oncology 2019-03, Vol.8 (1)
• Main Authors: Cobbs, Charles, McClay, Edward, Duic, J Paul, Nabors, L Burt, Morgan Murray, Donna, Kesari, Santosh
• Format: Article
• Language: English
• Subjects: Batteries; Brain cancer; brain tumor; Cancer therapies; Cell division; Chemotherapy; clinical trials; Electromagnetism; Feasibility studies; Gene expression; Glioblastoma multiforme; Magnetic fields; medical device; Medical equipment; Medical prognosis; Nervous system; novel therapy; Oncology; Patients; Personal health; Radiation therapy; Radio frequency; recurrent GBM; Short Communication; Tumors
• ISSN: 2045-0907; 2045-0915
• DOI: 10.2217/cns-2018-0013

Aim: Evaluation of the Nativis Voyager® device in patients with recurrent glioblastoma (rGBM). Materials & methods: Voyager is a noninvasive, nonthermal, nonionizing and portable investigational device which delivers ultra-low radio frequency energy (ulRFE®) that uses a magnetic field to penetrate tissues to alter specific biologic functions within cells. Patients with rGBM were treated with Voyager alone (V) or Voyager in combination with standard of care (V + SoC). Safety and clinical utility were assessed every 2–4 months. Results: Data from the first 11 patients treated are reported here. Median progression-free survival was 10 weeks in the V arm and 16 weeks in the V + SoC arm. Median overall survival was 16 months in V arm and 11 months in the V + SoC arm. No serious adverse events associated with the device were reported. Conclusion: These data suggest that the Voyager is safe and feasible for the treatment of rGBM